Epidermal growth factor receptor/angiogenesis dual targeting: Preclinical experience

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 330-334

  Bozec, Alexandre ^a   Fischel, Jean Louis ^a   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Anti angiogenic drugs; Epidermal growth factor receptor; Targeted therapy

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEINURIA; REVIEW; STOMACH CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33748077429     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228737.78003.06     Document Type: Review

References (39)

1. Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol 2004; 31:9-20.
2. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-250.
3. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer 2001; 7:1459-1465.
4. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 2:257-265.
5. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-2560.
6. Caponigro F, Formato R, Caraglia M, et al. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 2005; 17:212-217.
7. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64:4931-4941.
8. Thaker PH, Yazici S, Nilsson MB, et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 2005; 11:4923-4933. This paper reports the anti-tumor efficacy of a drug acting on both the EGFR and VEGFR2.
9. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9:1546-1556.
10. McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 9:1041-1048.
11. Williams KJ, Telfer BA, Brave S, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004; 10:8587-8593.
12. Tuccillo C, Romano M, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 2005; 11:1268-1276.
13. Bozec A, Formento P, Ciccolini J, et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005; 4:1962-1971.
14. O'Hare MJ, Bond J, Clarke C, et al. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci USA 2001; 98:646-651.
15. Hirata A, Uehara H, Izumi K, et al. Direct inhibition of EGF receptor activation in vascular endothelial by gefitinib ('Iressa' ZD1839). Cancer Sci 2004; 95:614-618.
16. Kallmann BA, Wagner S, Hummel V, et al. Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J 2002; 16:589-591.
17. Chen K, Vita JA, Berk BC, Keaney JF Jr. C-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J Biol Chem 2001; 276:16045-16050.
18. Hallahan DE, Virudachalam S, Sherman MA, et al. Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing irradiation. Cancer Res 1991; 51:4565-4569.
19. Hallahan DE, Sukatme VP, Sherman ML, et al. Protein kinase Cmediates X-ray inducibility of nuclear signal transducers EGFR1 and JUN. Proc Natl Acad Sci USA 1991; 88:2156-2160.
20. Sherman ML, Datta R, Hallahan DE, et al. Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA 1990; 87:5663-5666.
21. Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 1996; 145:81-85.
22. Friedmann B, Caplin M, Hartley JA, Hochlauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004; 10:6476-6486.
23. Thorpe PE, Chaplin DJ, Blakey D. The first international conference on vascular targeting: meeting overview. Cancer Res 2003; 63:1144-1147.
24. Hsieh HP, Liou JP, Mahindroo N. Pharmaceutical design of antimitotic agents based on combretastatins. Curr Pharm Des 2005; 11:1655-1677.
25. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-7253.
26. Nakaya H, Kawashiri S, Tanaka A, et al. Influences of angiogenesis and lymphangiogenesis on cancerous invasion in experimentally induced tongue carcinoma. J Oral Pathol Med 2005; 34:87-92.
27. Shang ZJ, Lir JR. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression. J Oral Pathol Med 2005; 34:134-139.
28. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31:734-743.
29. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carinoma. Curr Oncol Rep 2003; 5:140-146.
30. Pivot X, Magné N, Guardiola E, et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 2005; 41:320-327.
31. Etienne MC, Pivot X, Formento JL, et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999; 79:1864-1869.
32. Dassonville O, Formento JL, Francoual M. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11:1873-1878.
33. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10:3650-3657.
34. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8:1974-1983.
35. Skliarenko JV, Lunt SJ, Gordon ML, et al. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 2006; 66:2074-2080. This report describes synergistic cytotoxic interactions when combining the targeting of the EGFR with an anti-angiogenic drug and with irradiation.
36. Raben D, Bianco C, Damiano V, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 2004; 3:977-983.
37. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38:1133-1140.
38. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
39. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-2555.